In two separate studies on CEBPA mutations in acute myeloid leukemia (AML) subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase inhibitors, as potential candidates in the treatment of certain AML.